Literature DB >> 7519422

Transcriptional activation of the IL-6 response element in the junB promoter is mediated by multiple Stat family proteins.

Y Fujitani1, K Nakajima, H Kojima, K Nakae, T Takeda, T Hirano.   

Abstract

IL-6 signals activate an IL-6 response element in the junB promoter, JRE-IL6, in a Ras-independent manner. IL-6 rapidly induced a DNA-binding activity to the Ets binding site of JRE-IL6 (JEBS), one of necessary DNA motifs of the IL-6 response element. The IL-6-induced JEBS-binding activity was indistinguishable from those to acute phase response element (APRE) in both kinetics of induction and its DNA-binding specificity. Purified APRE binding factors (APRFs) from IL-6-stimulated rat liver were found to be composed of multiple Stat3-related proteins and Stat1. Moreover the purified APRFs specifically made a complex with JRE-IL6 with the same mobility as that observed in the crude extracts. These results indicate that an immediate early signal of IL-6 leading to activation of JRE-IL6 is mediated by STAT family transcription factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519422     DOI: 10.1006/bbrc.1994.2053

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  A novel nuclear zinc finger protein EZI enhances nuclear retention and transactivation of STAT3.

Authors:  Koh Nakayama; Kyung-Woon Kim; Atsushi Miyajima
Journal:  EMBO J       Date:  2002-11-15       Impact factor: 11.598

2.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

Authors:  B Belinda Ding; J Jessica Yu; Raymond Y-L Yu; Lourdes M Mendez; Rita Shaknovich; Yonghui Zhang; Giorgio Cattoretti; B Hilda Ye
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

3.  Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1.

Authors:  T Sekimoto; N Imamoto; K Nakajima; T Hirano; Y Yoneda
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

4.  A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells.

Authors:  K Nakajima; Y Yamanaka; K Nakae; H Kojima; M Ichiba; N Kiuchi; T Kitaoka; T Fukada; M Hibi; T Hirano
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

5.  Tissue-specific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells.

Authors:  M Narimatsu; H Maeda; S Itoh; T Atsumi; T Ohtani; K Nishida; M Itoh; D Kamimura; S J Park; K Mizuno; J Miyazaki; M Hibi; K Ishihara; K Nakajima; T Hirano
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

Review 6.  IL-6 cytokine family and signal transduction: a model of the cytokine system.

Authors:  M Hibi; K Nakajima; T Hirano
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

7.  Identification of the interleukin-6/oncostatin M response element in the rat tissue inhibitor of metalloproteinases-1 (TIMP-1) promoter.

Authors:  M Bugno; L Graeve; P Gatsios; A Koj; P C Heinrich; J Travis; T Kordula
Journal:  Nucleic Acids Res       Date:  1995-12-25       Impact factor: 16.971

8.  Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation.

Authors:  Y Yamanaka; K Nakajima; T Fukada; M Hibi; T Hirano
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

9.  Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation.

Authors:  Vicky Nicolaidou; Mei Mei Wong; Andia N Redpath; Adel Ersek; Dilair F Baban; Lynn M Williams; Andrew P Cope; Nicole J Horwood
Journal:  PLoS One       Date:  2012-07-03       Impact factor: 3.240

10.  Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease.

Authors:  Sorina Georgiana Boaru; Erawan Borkham-Kamphorst; Lidia Tihaa; Ute Haas; Ralf Weiskirchen
Journal:  J Inflamm (Lond)       Date:  2012-11-28       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.